Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC-Reference-Cited by-同舟云学术

Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC

Published:2021-03 Issue:3 Volume:16 Page:368-370
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Remon Jordi,Hendriks Lizza E.L.

Funder

AstraZeneca

Merck

Boehringer Ingelheim

Takeda Canada

Pfizer

Bristol-Myers Squibb

Merck Sharp and Dohme

Novartis Farmacéutica

Janssen Pharmaceuticals

Genentech

Eli Lilly and Company

GlaxoSmithKline

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference14 articles.

1. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2020

2. Osimertinib in resected EGFR-mutated non-small-cell lung cancer;Wu;N Engl J Med,2020

3. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial;Yue;Lancet Respir Med,2018

4. CTONG1104: adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial;Wu;J Clin Oncol,2020

5. Targeting cancer cell dormancy;Recasens;Trends Pharmacol Sci,2019

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of circulating-tumor DNA in the early-stage non-small cell lung carcinoma as a predictive biomarker;Pathology - Research and Practice;2023-05

2. Adjuvant treatment for resectable non-small cell lung cancer;Journal of the Korean Medical Association;2023-03-10

3. Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse;Tuberculosis and Respiratory Diseases;2023-01-01

4. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study;Clinical and Translational Oncology;2022-09-27

5. The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare;Cancers;2022-07-19